Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Semaglutide + GIP analogue) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
(Semaglutide + GIP analogue) is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes....